Blinatumomab
B-cell Acute Lymphoblastic Leukemia
SWOG Cancer Research Networkmonoclonal_antibodyPhase 4 / ApprovedActive
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 63/ 100
- Competitive Position
- 73/ 100
Competitive context
140 Active assets in the B-cell Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE University of Washington | Phase 3 | BBB |
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) City of Hope Medical Center | Phase 3 | BB |
VINCRISTINE SULFATE City of Hope Medical Center | Phase 3 | BB |
PEGASPARGASE National Cancer Institute (NCI) | Phase 3 | BB |
Dasatinib National Cancer Institute (NCI) | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Blinatumomab is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →